Pepgen announces appointment of two new directors to its board

Boston--(business wire)--pepgen inc. (nasdaq: pepg), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of lisa wyman and mitchell h. finer, phd, to its board of directors. ms. wyman and dr. finer are industry veterans, each bringing decades of executive experience in the life sciences to the company. “we are thrilled to w.
PEPG Ratings Summary
PEPG Quant Ranking